Tenax Therapeutics (NASDAQ:TENX) Announces Quarterly Earnings Results

Posted by George Bondi on May 13th, 2026

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05, FiscalAI reports.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX opened at $12.17 on Wednesday. The company’s fifty day moving average price is $13.79 and its 200-day moving average price is $12.08. The firm has a market capitalization of $209.30 million, a price-to-earnings ratio of -9.15 and a beta of 1.00. Tenax Therapeutics has a one year low of $5.34 and a one year high of $18.38.

Hedge Funds Weigh In On Tenax Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Tenax Therapeutics during the 3rd quarter valued at $92,000. Corient Private Wealth LLC bought a new position in shares of Tenax Therapeutics during the 4th quarter valued at $151,000. Quadrature Capital Ltd bought a new position in shares of Tenax Therapeutics during the 4th quarter valued at $252,000. Goldman Sachs Group Inc. bought a new position in shares of Tenax Therapeutics during the 4th quarter valued at $273,000. Finally, Citadel Advisors LLC grew its holdings in shares of Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock valued at $329,000 after purchasing an additional 32,908 shares during the last quarter. Institutional investors own 1.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. Guggenheim increased their target price on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Lifesci Capital upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, March 12th. Finally, Cantor Fitzgerald began coverage on shares of Tenax Therapeutics in a report on Tuesday, March 17th. They issued an “overweight” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $29.67.

Check Out Our Latest Stock Report on TENX

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.